BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 10784629)

  • 1. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.
    Maris JM; Weiss MJ; Guo C; Gerbing RB; Stram DO; White PS; Hogarty MD; Sulman EP; Thompson PM; Lukens JN; Matthay KK; Seeger RC; Brodeur GM
    J Clin Oncol; 2000 May; 18(9):1888-99. PubMed ID: 10784629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of chromosome 1p deletions in neuroblastoma.
    Maris JM; Guo C; Blake D; White PS; Hogarty MD; Thompson PM; Rajalingam V; Gerbing R; Stram DO; Matthay KK; Seeger RC; Brodeur GM
    Med Pediatr Oncol; 2001 Jan; 36(1):32-6. PubMed ID: 11464900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
    Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
    Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations.
    Spitz R; Hero B; Westermann F; Ernestus K; Schwab M; Berthold F
    Genes Chromosomes Cancer; 2002 Jul; 34(3):299-305. PubMed ID: 12007190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosome 1p and 11q deletions and outcome in neuroblastoma.
    Attiyeh EF; London WB; Mossé YP; Wang Q; Winter C; Khazi D; McGrady PW; Seeger RC; Look AT; Shimada H; Brodeur GM; Cohn SL; Matthay KK; Maris JM;
    N Engl J Med; 2005 Nov; 353(21):2243-53. PubMed ID: 16306521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma.
    Yue ZX; Xing TY; Zhao W; Zhao Q; Wang XS; Su Y; Gao C; Liu SG; Ma XL
    Cancer Med; 2022 Apr; 11(8):1837-1849. PubMed ID: 35137546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1.
    Hiyama E; Hiyama K; Ohtsu K; Yamaoka H; Fukuba I; Matsuura Y; Yokoyama T
    Med Pediatr Oncol; 2001 Jan; 36(1):67-74. PubMed ID: 11464909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavourable outcome.
    Iolascon A; Lo Cunsolo C; Giordani L; Cusano R; Mazzocco K; Boumgartner M; Ghisellini P; Faienza MF; Boni L; De Bernardi B; Conte M; Romeo G; Tonini GP
    Cancer Lett; 1998 Aug; 130(1-2):83-92. PubMed ID: 9751260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.
    Maris JM; Guo C; White PS; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM
    Med Pediatr Oncol; 2001 Jan; 36(1):24-7. PubMed ID: 11464895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.
    Perez CA; Matthay KK; Atkinson JB; Seeger RC; Shimada H; Haase GM; Stram DO; Gerbing RB; Lukens JN
    J Clin Oncol; 2000 Jan; 18(1):18-26. PubMed ID: 10623689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease.
    Mora J; Cheung NK; Chen L; Qin J; Gerald W
    Cancer; 2001 Jan; 91(2):435-42. PubMed ID: 11180092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of heterozygosity for chromosome 14q in neuroblastoma.
    Thompson PM; Seifried BA; Kyemba SK; Jensen SJ; Guo C; Maris JM; Brodeur GM; Stram DO; Seeger RC; Gerbing R; Matthay KK; Matise TC; White PS
    Med Pediatr Oncol; 2001 Jan; 36(1):28-31. PubMed ID: 11464899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN.
    Teitz T; Wei T; Liu D; Valentine V; Valentine M; Grenet J; Lahti JM; Kidd VJ
    Oncogene; 2002 Mar; 21(12):1848-58. PubMed ID: 11896617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma.
    Mora J; Gerald WL; Qin J; Cheung NK
    Cancer; 2002 May; 94(10):2756-65. PubMed ID: 12173347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
    J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of the putative tumor suppressor-gene locus 1p36 as investigated by a PCR-assay and N-myc amplification in 48 neuroblastomas: results of the German Neuroblastoma Study Group.
    Christiansen H; Delattre O; Fuchs S; Theobald M; Christiansen NM; Berthold F; Lampert F
    Prog Clin Biol Res; 1994; 385():19-25. PubMed ID: 7972212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
    Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
    Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.
    Matthay KK; Perez C; Seeger RC; Brodeur GM; Shimada H; Atkinson JB; Black CT; Gerbing R; Haase GM; Stram DO; Swift P; Lukens JN
    J Clin Oncol; 1998 Apr; 16(4):1256-64. PubMed ID: 9552023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.